Navigation Links
Combination of Meniscus Allograft Transplantation and Repair of Articular Cartilage May Slow the Progression of Arthritis in the Knee
Date:7/7/2010

Stone Research Foundation Publishes Study Results in The British Journal of Bone & Joint Surgery, Showing a 9.9 Year Survival Rate. Success of Less Invasive Procedures for Knee Damage Could Help Lower Skyrocketing Instances of Knee Replacement Surgery

San Francisco, CA (PRWEB) July 7, 2010 -- Biologic knee repair, rather than bionic (artificial) replacement, may slow the progression of arthritis without limiting the option for future arthroplasty, according to a study by Kevin R. Stone, MD, chairman, the Stone Research Foundation in this month’s issue of The British Journal of Bone & Joint Surgery. These research results could have significant impact on the long-term feasibility of artificial knee replacement - the number of artificial joint replacement surgeries is predicted to increase to 3.4 million by 2030, with proportionate increases in cost. The goal of biologic knee repair, according to Dr. Stone, is to avoid or forestall knee replacement surgery.

The report is based on a study of 119 meniscal allograft transplantations performed concurrently with articular cartilage repair in 115 patients with severe articular cartilage damage. The Kaplan-Meier estimated mean survival time for the whole series was 9.9 years. Loss of the meniscus generates increased forces on the articular cartilage of the knee and other joint structures and increases the risk of the development of arthritis. The appropriate treatment for loss of the meniscus with unicompartmental arthritis remains controversial, with treatments including osteotomy, unicompartmental (UKR) or total knee replacement. The study was approved by an independent Institutional Review Board. The study abstract is available via The British Journal of Bone & Joint Surgery.

Co-authors of the study with Dr. Stone are Ann W. Walgenbach, RNNP; Wendy Adelson, MS; Jonathan Pelsis, MHP; and Tom Turek of The Stone Research Foundation, San Francisco.

About The Stone Research Foundation:
The Stone Research Foundation is an independent, public, non-profit research institute based in San Francisco. Its mission is to research and develop ways to prevent, treat, and reverse arthritis and joint injuries. More info is available at www.stoneresearch.org.

###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4231024.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Combination MMRV vaccine linked with 2-fold risk of seizures
2. Noninvasive combination technique may reduce number of breast biopsies
3. New combination effective against pancreatic cancer
4. Combination treatment regimen not effective against advanced melanoma
5. Combination therapy targets stubborn leukemia stem cells
6. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
7. Combination antibiotics effective against chlamydia-induced arthritis
8. Leeza Gibbons and ZERONA Equals a Winning Combination
9. Researchers find new chemotherapy combination shows promise in endometrial cancer
10. Combination Treatment May Help Depressed Alcoholics
11. Combination therapy more effective for enlarged prostate
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combination of Meniscus Allograft Transplantation and Repair of Articular Cartilage May Slow the Progression of Arthritis in the Knee 
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... Pa. , Oct. 10, 2017   West ... in innovative solutions for injectable drug administration, today shared ... West,s ID Adapter for improving the intradermal administration of ... Fourth Skin Vaccination Summit in May 2017 by Dr. ... Lead, Polio Department, World Health Organization (WHO), and recently ...
Breaking Medicine Technology: